In some cases, treatment for underlying conditions, such as type 2 diabetes, are recommended and may include weight loss medications and/or weight loss surgery
doi:10.1016/j.freeradbiomed.2017.02.041 275
The drug class includes semaglutide (branded as Ozempic for diabetes and Wegovy for chronic weight management), tirzepatide (Mounjaro and Zepbound), and liraglutide (Saxenda)
The present analysis demonstrated that oral semaglutide is efficacious and cost-effective in varying patient populations versus comparators for patients with type 2 diabetes receiving differing background therapies, indicating it is a viable treatment option for a variety of patients, irrespective of prior treatment
[DOI] [PubMed] [Google Scholar] 157.Gimbrone M.A., Cotran R.S., Leapman S.B., Folkman J
Shorter monitoring periods are often clinically appropriate when physiologic data is needed during defined windows of care